The information you provide to the chat will be collected and recorded to improve your experience and for quality assurance. Please read our privacy policy to see how we are storing and protecting your data.
How can we help you today?
We're proud to receive a 2025 CDMO Leadership Award in the “Small Molecule Dosage Form - Global" category.
Search Patheon
Recent searches
Clear History
Suggestions
All Results
Recent searches
Clear History
Suggestions
All Results
Search
US | EN
Evaluating current manufacturing platforms for recombinant AAV production
Whitepaper
Gene therapies offer promising solutions for chronic, rare, and genetic diseases, primarily through viral vectors delivering therapeutic genes to target cells. Adeno-associated virus (AAV) vectors are notable for their efficiency and safety. With 13 known serotypes and over 100 variants, plus ongoing development of new serotypes for better tissue targeting, AAV vectors are highly versatile. Their ability to infect both dividing and non-dividing cells without integrating into the host genome makes them ideal for long-term gene expression.
Efficient and scalable production of high-quality AAV vectors is critical for the success of these therapies, and robust manufacturing platforms are essential. As the gene therapy market grows, evaluating manufacturing platforms for specific critical quality attributes (CQAs) is crucial. Understanding these factors helps stakeholders make informed decisions, driving the advancement of gene therapies.
Download our whitepaper to explore current manufacturing platforms for recombinant AAV production.
